Legend Biotech Financial Ratios
NASDAQ: LEGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Legend Biotech ratio analysis
Legend Biotech earned a net margin of -28.8% in FY 2025, down from -28.2% a year earlier. Gross margin was 61.4% compared with a median of 65.5% over the prior 5 years. Return on equity reached -29.6%, meaning Legend Biotech generated -0.30 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.32 versus 0.29 the year before, and the current ratio was 1.96. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Legend Biotech financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Price / sales | 7.71 | 20.86 | 74.31 | 135.71 | 190.77 | 88.72 | — | — |
| Price / book | 7.91 | 12.57 | 16.93 | 21.33 | 17.14 | 11.13 | — | — |
| Gross margin | 61.4% | 65.5% | 49.4% | 44.1% | 100.0% | 100.0% | — | — |
| Operating margin | -13.3% | -49.3% | -185.2% | — | — | — | — | — |
| Net margin | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -169.4% | -5.7% |
| Free cash flow margin | -12.5% | -25.2% | -145.0% | -189.9% | -349.7% | -332.3% | -183.1% | 583.6% |
| Return on equity (ROE) | -29.6% | -17.0% | -41.4% | -60.0% | -52.7% | -44.6% | — | -1.1% |
| Return on assets (ROA) | -17.1% | -10.6% | -28.0% | -33.5% | -36.1% | -36.9% | -35.3% | — |
| Debt / equity | 0.32 | 0.29 | 0.22 | 0.35 | 0.16 | — | — | — |
| Current ratio | 1.96 | 4.62 | 6.92 | 3.69 | 4.14 | 5.14 | 1.62 | — |
| Revenue growth | 64.0% | 120.0% | 143.7% | 70.0% | -8.2% | 25.0% | 22.1% | — |